{"ticker": {"uuid": "e87ae051-5953-43aa-97e5-132814dcdeea", "symbol": "JNJ", "name": "Johnson & Johnson", "exchange": "GER", "country": "DE", "sector": "Healthcare", "industry": "Drug Manufacturers - General"}, "articles": [{"title": "Intuitive Surgical (ISRG) Beats On Q2 As Investors Ask If The Bull Case Is Priced In", "summary": "Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Intuitive Surgical (ISRG) shook investors after reporting strong Q2 2026 revenue and earnings that beat expectations, while revealing slower U.S. procedure growth and rising competitive pressure from Johnson & Johnson and Chinese robotic surgery platforms. See our latest analysis for Intuitive Surgical. The Q2 surprise arrives after a tough stretch for Intuitive Surgical, with the share price down 28.6% year to date and the 1 year total shareholder return ", "url": "https://finance.yahoo.com/markets/stocks/articles/intuitive-surgical-isrg-beats-q2-211316667.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T21:13:16+00:00", "published_display": "12 Aug 2026 21:13", "sentiment": "positive", "sentiment_pct": 85, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.292, "duplicate_count": 1, "topics": ["Earnings", "Medical Equipment", "Revenue Growth", "Share Price", "Shareholder", "Split"]}, {"title": "Johnson & Johnson (JNJ) Advances Seltorexant And Expands Outpatient Cardiac Care", "summary": "Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Johnson & Johnson (NYSE: JNJ) is advancing its novel antidepressant Seltorexant into late stage clinical development for major depressive disorder as a potential rapid acting treatment option. The company also entered a multi year partnership with ACCESS to expand adoption of advanced cardiac electrophysiology technologies in ambulatory surgery centers. Both moves align with Johnson & Johnson's focus on higher growth therapeutic and medtech areas that are important for its lo", "url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-advances-seltorexant-161141375.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T16:11:41+00:00", "published_display": "12 Aug 2026 16:11", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.317, "duplicate_count": 1, "topics": ["Cardiovascular", "Clinical Trials", "Medtech", "Neuroscience", "Pharmaceuticals", "Revenue Growth"]}, {"title": "Intuitive Surgical: Oppenheimer now bullish, sees competition being \"crowded out\"", "summary": "Investing.com -- Oppenheimer upgraded Intuitive Surgical to Outperform from Perform with a $500 price target in a note on Wednesday, arguing the company's strategy of \"Crowding Out Competitors\" is strategically smart. Analyst Suraj Kalia said the change reflects \"a more nuanced risk-reward assessment at these levels.\" On the positive side, the firm views U.S. competition as a \"non-factor,\" with field checks suggesting \"some unique workflow challenges for Ottava that limit long-term appeal\" and real-estate issues for Hugo. It added that Intuitive's customized price-volume contracts complicate c", "url": "https://finance.yahoo.com/healthcare/articles/intuitive-surgical-oppenheimer-now-bullish-125931309.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T12:59:31+00:00", "published_display": "12 Aug 2026 12:59", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.204, "duplicate_count": 1, "topics": ["Healthcare", "Price Target", "Price Target", "Robotic Surgery", "Upgrade Downgrade"]}, {"title": "Oppenheimer Sees $500 for Intuitive Surgical as Rivals Stall", "summary": "This article first appeared on GuruFocus. Intuitive Surgical (NASDAQ:ISRG) rose 0.90% premarket after Oppenheimer upgraded the robotic surgery company to Outperform from Perform with a $500 price target. The firm's case rests less on Intuitive than on its competitors: workflow integration problems for Johnson & Johnson's (NYSE:JNJ) Ottava system and physical footprint constraints for Medtronic's (NYSE:MDT) Hugo, potentially leaving the da Vinci franchise without a credible domestic challenger in the near term. Oppenheimer also pointed to the Per Click Model as a way into lower-acuity ambulator", "url": "https://finance.yahoo.com/markets/stocks/articles/oppenheimer-sees-500-intuitive-surgical-122519688.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T12:25:19+00:00", "published_display": "12 Aug 2026 12:25", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.215, "duplicate_count": 1, "topics": ["Price Target", "Price Target", "Robotic Surgery", "Upgrade Downgrade"]}, {"title": "Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors", "summary": "Madrigal Pharmaceuticals, Inc. CONSHOHOCKEN, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced it has appointed John C. Reed, M.D., Ph.D., to its Board of Directors. Dr. Reed currently serves as Executive Vice President, Innovative Medicine, Research & Development at Johnson & Johnson (\"J&J\") and is a member of J&J's Executive Committee, where he leads research and development across oncology, immunology, neuroscie", "url": "https://finance.yahoo.com/healthcare/articles/madrigal-appoints-john-c-reed-120000934.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T12:00:00+00:00", "published_display": "12 Aug 2026 12:00", "sentiment": "positive", "sentiment_pct": 63, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.314, "duplicate_count": 1, "topics": ["Biotech", "Fda Approval", "Mash", "Press Releases"]}, {"title": "How Much Did Immunology Drugs Contribute to AbbVie's Q2 Performance?", "summary": "AbbVie ABBV announced encouraging second-quarter 2026 results last month, which beat expectations for both earnings and sales. A significant portion of this growth came from the continued strength of its two blockbuster immunology medications, Skyrizi and Rinvoq, which together accounted for more than 47% of total revenues. Skyrizi sales jumped 24% year over year on an operational basis to $5.5 billion, while Rinvoq sales rose 23.7% to more than $2.5 billion. Both drugs benefited from strong demand and market-share gains across their approved indications, especially in the popular inflammatory", "url": "https://finance.yahoo.com/healthcare/articles/much-did-immunology-drugs-contribute-165400709.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T16:54:00+00:00", "published_display": "11 Aug 2026 16:54", "sentiment": "positive", "sentiment_pct": 90, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.223, "duplicate_count": 1, "topics": ["Biotech", "Competition", "Earnings", "Fda Approval", "Immunology"]}, {"title": "J&J Trading Above 200- & 50-Day SMAs: Buy, Sell or Hold the Stock?", "summary": "Johnson & Johnson JNJ stock has been trading above both its 50-day and 200-day simple moving averages (SMAs) since mid-June. Trading above the 200-day SMA indicates that the stock's longer-term trend has turned positive, while staying above the 50-day SMA suggests that shorter-term momentum remains supportive. When a stock trades above both averages, investors generally interpret it as evidence that buying interest is strong enough to keep the shares above their medium- and long-term trend levels.Zacks Investment Research Image Source: Zacks Investment Research This strong share price performa", "url": "https://finance.yahoo.com/markets/stocks/articles/j-j-trading-above-200-131200196.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T13:12:00+00:00", "published_display": "11 Aug 2026 13:12", "sentiment": "positive", "sentiment_pct": 86, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.214, "duplicate_count": 1, "topics": ["Earnings", "Innovative Medicine", "Litigation", "Medtech", "Patent Expiration", "Share Price"]}, {"title": "What Johnson & Johnson (JNJ)'s OTTAVA FDA Win and Talc Deal Shift Mean For Shareholders", "summary": "In recent months, Johnson & Johnson reported strong Q2 2026 results, received FDA De Novo authorization for its OTTAVA soft-tissue robotic surgery system, advanced its RYBREVANT FASPRO oncology franchise with an FDA Priority Review, announced a US$5.50 billion talc settlement framework, and agreed to collaborate with Sail Biomedicines on in vivo CAR-T therapies. Together with leadership changes in its Innovative Medicine unit and new MedTech and electrophysiology partnerships, these developments highlight Johnson & Johnson's effort to reposition around higher-growth innovative medicines and me", "url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-ottava-fda-002047054.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T00:20:47+00:00", "published_display": "11 Aug 2026 00:20", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.266, "duplicate_count": 1, "topics": ["Fda Approval", "Litigation", "Medtech", "Oncology", "Revenue Growth", "Robotics"]}, {"title": "Johnson & Johnson vs. Medtronic: Which Healthcare Stock Is Better Positioned After Earnings?", "summary": "Johnson & Johnson (NYSE:JNJ) delivered another strong quarter in fiscal Q2 2026, with reported sales increasing 6.6% year over year to $25.31 billion and surpassing analysts' average estimate of around $25.05 billion. Adjusted earnings per share reached $2.90, also exceeding estimates of $2.85. The healthcare giant raised its full-year outlook and said it remains on track to generate more than $100 billion in annual revenue for the first time in its 140-year history. Medtronic (NYSE:MDT), meanwhile, ended fiscal 2026 with its fastest annual revenue growth in a decade. Several newer products ar", "url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-vs-medtronic-healthcare-223657921.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T22:36:57+00:00", "published_display": "10 Aug 2026 22:36", "sentiment": "positive", "sentiment_pct": 85, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.209, "duplicate_count": 1, "topics": ["Earnings", "Earnings Growth", "Earnings Per Share", "Guidance", "Healthcare", "Medical Devices"]}, {"title": "Johnson & Johnson vs Abbott Laboratories: Which Healthcare Giant Offers the More Compelling Growth Story After Earnings?", "summary": "Johnson & Johnson (NYSE:JNJ) delivered strong fiscal Q2 2026 results, with sales for the quarter growing nearly 7% to $25.31 \u2060billion, above analysts' average estimate of about $25.05 billion. Adjusted earnings per share reached $2.90, surpassing the expectation of $2.85. The company also raised its guidance and stated that it is on track to meet its 2026 goal of over $100 billion in annual revenue for the first time in its 140-year history. Abbott Laboratories (NYSE:ABT) also beat its quarterly estimates in its fiscal Q2 2026 results while also raising its annual profit forecast, with strong ", "url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-vs-abbott-laboratories-204959195.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T20:49:59+00:00", "published_display": "10 Aug 2026 20:49", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.224, "duplicate_count": 1, "topics": ["Diagnostics", "Earnings", "Earnings Growth", "Earnings Per Share", "Guidance", "Healthcare"]}, {"title": "Jim Cramer Highlights Pharmaceutical Giants as Non-Tech Innovation Plays Like JNJ and LLY", "summary": "During the August 6 episode of CNBC's Mad Money, Jim Cramer pointed to a growing sector rotation as portfolio managers look for innovation outside the mega-cap technology space. He said: Finally, tech had such a run that portfolio managers want exposure to other sectors of the market that still have innovation. Think of them as non- tech tech stocks. For the\u2026 Charitable Trust club, we've been emphasizing Eli Lilly and Johnson & Johnson. And we talked about these\u2026 I talked about them at length with Jeff Marks today at our 10:20 call. They both had terrific quarters and deserve to be bought on a", "url": "https://finance.yahoo.com/healthcare/articles/jim-cramer-highlights-pharmaceutical-giants-180730894.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T18:07:30+00:00", "published_display": "10 Aug 2026 18:07", "sentiment": "neutral", "sentiment_pct": 54, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.122, "duplicate_count": 1, "topics": ["Balance Sheet", "Biotech", "Fda Approval", "Fourth Quarter", "Healthcare", "M A"]}, {"title": "ISRG Trades at a Premium P/E: Buy, Sell or Hold the Stock Now?", "summary": "Intuitive Surgical ISRG currently trades at a forward 12-month P/E ratio of 33.02X, above the Medical - Instruments industry's 26.53X, underscoring a valuation premium that investors must weigh against the company's growth prospects. The stock carries a Value Score of D, suggesting that shares are not particularly inexpensive despite the compression in its valuation multiple. Second-quarter 2026 results nevertheless provided a solid operating baseline. Revenues increased 19% year over year to $2.89 billion, while adjusted earnings per share (EPS) rose 28% to $2.80. Total procedures increased 1", "url": "https://finance.yahoo.com/healthcare/articles/isrg-trades-premium-p-e-144200115.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T14:42:00+00:00", "published_display": "10 Aug 2026 14:42", "sentiment": "positive", "sentiment_pct": 87, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.19, "duplicate_count": 1, "topics": ["Earnings", "Earnings Per Share", "Fda Approval", "Guidance", "Medical Instruments", "Revenue Growth"]}, {"title": "Can Johnson & Johnson (JNJ) Challenge Intuitive Surgical (ISRG) After Ottava\u2019s FDA Approval?", "summary": "Johnson & Johnson (NYSE:JNJ) has officially entered the U.S. soft-tissue robotic surgery market after receiving FDA De Novo authorization for its OTTAVA robotic surgical system. The authorization represents an important milestone for J&J's MedTech ambitions, but the company is entering a market in which Intuitive Surgical (NASDAQ:ISRG) already has an extensive installed base, established surgeon relationships, and a rapidly expanding da Vinci 5 platform. The question for investors is not whether OTTAVA can become a viable product, but whether Johnson & Johnson (NYSE:JNJ) can convert its differ", "url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-challenge-intuitive-124242559.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T12:42:42+00:00", "published_display": "10 Aug 2026 12:42", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.208, "duplicate_count": 1, "topics": ["Fda Approval", "Financial Results", "Healthcare", "Medtech", "Robotic Surgery"]}, {"title": "ACCESS Announces Multi-Year Strategic Agreement to Bring Advanced Cardiac Electrophysiology Technologies to Ambulatory Surgery Centers", "summary": "Agreement supports ACCESS-affiliated ASCs in adopting the CARTO\u2122 System and its integrated portfolio of mapping, intracardiac imaging, radiofrequency ablation and pulsed field ablation technologies NEW YORK, August 10, 2026--(BUSINESS WIRE)--ACCESS, through its physician-led group purchasing organization, ACCESS GPO, today announced a multi-year preferred portfolio agreement with Johnson & Johnson to support the adoption of advanced cardiac electrophysiology technologies in ambulatory surgery centers (ASC) across the United States. The agreement encompasses an integrated portfolio of three-dim", "url": "https://finance.yahoo.com/healthcare/articles/access-announces-multi-strategic-agreement-110000847.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T11:00:00+00:00", "published_display": "10 Aug 2026 11:00", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.128, "duplicate_count": 1, "topics": ["Ambulatory Surgery Centers", "Cardiovascular Care", "Electrophysiology"]}, {"title": "Johnson & Johnson (JNJ) Reaches $5.5 Billion Talc Settlement To Close Years Of Lawsuits", "summary": "Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Johnson & Johnson (NYSE: JNJ) agreed to a US$5.5b settlement to resolve tens of thousands of talc baby powder lawsuits. The deal ends decades of litigation over alleged health risks tied to the company's talc-based products. The settlement follows years of high profile trials and failed bankruptcy attempts related to the talc claims. This resolution removes a long running legal overhang and brings more clarity for Johnson & Johnson investors. Consider broadening your research to o", "url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-reaches-5-191035095.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-07T19:10:35+00:00", "published_display": "07 Aug 2026 19:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.157, "duplicate_count": 1, "topics": ["Balance Sheet", "Consumer Health", "Legal Issues", "Settlement"]}], "by_tier": {"direct": [{"title": "Intuitive Surgical (ISRG) Beats On Q2 As Investors Ask If The Bull Case Is Priced In", "summary": "Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Intuitive Surgical (ISRG) shook investors after reporting strong Q2 2026 revenue and earnings that beat expectations, while revealing slower U.S. procedure growth and rising competitive pressure from Johnson & Johnson and Chinese robotic surgery platforms. See our latest analysis for Intuitive Surgical. The Q2 surprise arrives after a tough stretch for Intuitive Surgical, with the share price down 28.6% year to date and the 1 year total shareholder return ", "url": "https://finance.yahoo.com/markets/stocks/articles/intuitive-surgical-isrg-beats-q2-211316667.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T21:13:16+00:00", "published_display": "12 Aug 2026 21:13", "sentiment": "positive", "sentiment_pct": 85, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.292, "duplicate_count": 1, "topics": ["Earnings", "Medical Equipment", "Revenue Growth", "Share Price", "Shareholder", "Split"]}, {"title": "Johnson & Johnson (JNJ) Advances Seltorexant And Expands Outpatient Cardiac Care", "summary": "Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Johnson & Johnson (NYSE: JNJ) is advancing its novel antidepressant Seltorexant into late stage clinical development for major depressive disorder as a potential rapid acting treatment option. The company also entered a multi year partnership with ACCESS to expand adoption of advanced cardiac electrophysiology technologies in ambulatory surgery centers. Both moves align with Johnson & Johnson's focus on higher growth therapeutic and medtech areas that are important for its lo", "url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-advances-seltorexant-161141375.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T16:11:41+00:00", "published_display": "12 Aug 2026 16:11", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.317, "duplicate_count": 1, "topics": ["Cardiovascular", "Clinical Trials", "Medtech", "Neuroscience", "Pharmaceuticals", "Revenue Growth"]}, {"title": "Intuitive Surgical: Oppenheimer now bullish, sees competition being \"crowded out\"", "summary": "Investing.com -- Oppenheimer upgraded Intuitive Surgical to Outperform from Perform with a $500 price target in a note on Wednesday, arguing the company's strategy of \"Crowding Out Competitors\" is strategically smart. Analyst Suraj Kalia said the change reflects \"a more nuanced risk-reward assessment at these levels.\" On the positive side, the firm views U.S. competition as a \"non-factor,\" with field checks suggesting \"some unique workflow challenges for Ottava that limit long-term appeal\" and real-estate issues for Hugo. It added that Intuitive's customized price-volume contracts complicate c", "url": "https://finance.yahoo.com/healthcare/articles/intuitive-surgical-oppenheimer-now-bullish-125931309.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T12:59:31+00:00", "published_display": "12 Aug 2026 12:59", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.204, "duplicate_count": 1, "topics": ["Healthcare", "Price Target", "Price Target", "Robotic Surgery", "Upgrade Downgrade"]}, {"title": "Oppenheimer Sees $500 for Intuitive Surgical as Rivals Stall", "summary": "This article first appeared on GuruFocus. Intuitive Surgical (NASDAQ:ISRG) rose 0.90% premarket after Oppenheimer upgraded the robotic surgery company to Outperform from Perform with a $500 price target. The firm's case rests less on Intuitive than on its competitors: workflow integration problems for Johnson & Johnson's (NYSE:JNJ) Ottava system and physical footprint constraints for Medtronic's (NYSE:MDT) Hugo, potentially leaving the da Vinci franchise without a credible domestic challenger in the near term. Oppenheimer also pointed to the Per Click Model as a way into lower-acuity ambulator", "url": "https://finance.yahoo.com/markets/stocks/articles/oppenheimer-sees-500-intuitive-surgical-122519688.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T12:25:19+00:00", "published_display": "12 Aug 2026 12:25", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.215, "duplicate_count": 1, "topics": ["Price Target", "Price Target", "Robotic Surgery", "Upgrade Downgrade"]}, {"title": "Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors", "summary": "Madrigal Pharmaceuticals, Inc. CONSHOHOCKEN, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced it has appointed John C. Reed, M.D., Ph.D., to its Board of Directors. Dr. Reed currently serves as Executive Vice President, Innovative Medicine, Research & Development at Johnson & Johnson (\"J&J\") and is a member of J&J's Executive Committee, where he leads research and development across oncology, immunology, neuroscie", "url": "https://finance.yahoo.com/healthcare/articles/madrigal-appoints-john-c-reed-120000934.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T12:00:00+00:00", "published_display": "12 Aug 2026 12:00", "sentiment": "positive", "sentiment_pct": 63, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.314, "duplicate_count": 1, "topics": ["Biotech", "Fda Approval", "Mash", "Press Releases"]}, {"title": "How Much Did Immunology Drugs Contribute to AbbVie's Q2 Performance?", "summary": "AbbVie ABBV announced encouraging second-quarter 2026 results last month, which beat expectations for both earnings and sales. A significant portion of this growth came from the continued strength of its two blockbuster immunology medications, Skyrizi and Rinvoq, which together accounted for more than 47% of total revenues. Skyrizi sales jumped 24% year over year on an operational basis to $5.5 billion, while Rinvoq sales rose 23.7% to more than $2.5 billion. Both drugs benefited from strong demand and market-share gains across their approved indications, especially in the popular inflammatory", "url": "https://finance.yahoo.com/healthcare/articles/much-did-immunology-drugs-contribute-165400709.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T16:54:00+00:00", "published_display": "11 Aug 2026 16:54", "sentiment": "positive", "sentiment_pct": 90, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.223, "duplicate_count": 1, "topics": ["Biotech", "Competition", "Earnings", "Fda Approval", "Immunology"]}, {"title": "J&J Trading Above 200- & 50-Day SMAs: Buy, Sell or Hold the Stock?", "summary": "Johnson & Johnson JNJ stock has been trading above both its 50-day and 200-day simple moving averages (SMAs) since mid-June. Trading above the 200-day SMA indicates that the stock's longer-term trend has turned positive, while staying above the 50-day SMA suggests that shorter-term momentum remains supportive. When a stock trades above both averages, investors generally interpret it as evidence that buying interest is strong enough to keep the shares above their medium- and long-term trend levels.Zacks Investment Research Image Source: Zacks Investment Research This strong share price performa", "url": "https://finance.yahoo.com/markets/stocks/articles/j-j-trading-above-200-131200196.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T13:12:00+00:00", "published_display": "11 Aug 2026 13:12", "sentiment": "positive", "sentiment_pct": 86, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.214, "duplicate_count": 1, "topics": ["Earnings", "Innovative Medicine", "Litigation", "Medtech", "Patent Expiration", "Share Price"]}, {"title": "What Johnson & Johnson (JNJ)'s OTTAVA FDA Win and Talc Deal Shift Mean For Shareholders", "summary": "In recent months, Johnson & Johnson reported strong Q2 2026 results, received FDA De Novo authorization for its OTTAVA soft-tissue robotic surgery system, advanced its RYBREVANT FASPRO oncology franchise with an FDA Priority Review, announced a US$5.50 billion talc settlement framework, and agreed to collaborate with Sail Biomedicines on in vivo CAR-T therapies. Together with leadership changes in its Innovative Medicine unit and new MedTech and electrophysiology partnerships, these developments highlight Johnson & Johnson's effort to reposition around higher-growth innovative medicines and me", "url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-ottava-fda-002047054.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T00:20:47+00:00", "published_display": "11 Aug 2026 00:20", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.266, "duplicate_count": 1, "topics": ["Fda Approval", "Litigation", "Medtech", "Oncology", "Revenue Growth", "Robotics"]}, {"title": "Johnson & Johnson vs. Medtronic: Which Healthcare Stock Is Better Positioned After Earnings?", "summary": "Johnson & Johnson (NYSE:JNJ) delivered another strong quarter in fiscal Q2 2026, with reported sales increasing 6.6% year over year to $25.31 billion and surpassing analysts' average estimate of around $25.05 billion. Adjusted earnings per share reached $2.90, also exceeding estimates of $2.85. The healthcare giant raised its full-year outlook and said it remains on track to generate more than $100 billion in annual revenue for the first time in its 140-year history. Medtronic (NYSE:MDT), meanwhile, ended fiscal 2026 with its fastest annual revenue growth in a decade. Several newer products ar", "url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-vs-medtronic-healthcare-223657921.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T22:36:57+00:00", "published_display": "10 Aug 2026 22:36", "sentiment": "positive", "sentiment_pct": 85, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.209, "duplicate_count": 1, "topics": ["Earnings", "Earnings Growth", "Earnings Per Share", "Guidance", "Healthcare", "Medical Devices"]}, {"title": "Johnson & Johnson vs Abbott Laboratories: Which Healthcare Giant Offers the More Compelling Growth Story After Earnings?", "summary": "Johnson & Johnson (NYSE:JNJ) delivered strong fiscal Q2 2026 results, with sales for the quarter growing nearly 7% to $25.31 \u2060billion, above analysts' average estimate of about $25.05 billion. Adjusted earnings per share reached $2.90, surpassing the expectation of $2.85. The company also raised its guidance and stated that it is on track to meet its 2026 goal of over $100 billion in annual revenue for the first time in its 140-year history. Abbott Laboratories (NYSE:ABT) also beat its quarterly estimates in its fiscal Q2 2026 results while also raising its annual profit forecast, with strong ", "url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-vs-abbott-laboratories-204959195.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T20:49:59+00:00", "published_display": "10 Aug 2026 20:49", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.224, "duplicate_count": 1, "topics": ["Diagnostics", "Earnings", "Earnings Growth", "Earnings Per Share", "Guidance", "Healthcare"]}, {"title": "Jim Cramer Highlights Pharmaceutical Giants as Non-Tech Innovation Plays Like JNJ and LLY", "summary": "During the August 6 episode of CNBC's Mad Money, Jim Cramer pointed to a growing sector rotation as portfolio managers look for innovation outside the mega-cap technology space. He said: Finally, tech had such a run that portfolio managers want exposure to other sectors of the market that still have innovation. Think of them as non- tech tech stocks. For the\u2026 Charitable Trust club, we've been emphasizing Eli Lilly and Johnson & Johnson. And we talked about these\u2026 I talked about them at length with Jeff Marks today at our 10:20 call. They both had terrific quarters and deserve to be bought on a", "url": "https://finance.yahoo.com/healthcare/articles/jim-cramer-highlights-pharmaceutical-giants-180730894.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T18:07:30+00:00", "published_display": "10 Aug 2026 18:07", "sentiment": "neutral", "sentiment_pct": 54, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.122, "duplicate_count": 1, "topics": ["Balance Sheet", "Biotech", "Fda Approval", "Fourth Quarter", "Healthcare", "M A"]}, {"title": "ISRG Trades at a Premium P/E: Buy, Sell or Hold the Stock Now?", "summary": "Intuitive Surgical ISRG currently trades at a forward 12-month P/E ratio of 33.02X, above the Medical - Instruments industry's 26.53X, underscoring a valuation premium that investors must weigh against the company's growth prospects. The stock carries a Value Score of D, suggesting that shares are not particularly inexpensive despite the compression in its valuation multiple. Second-quarter 2026 results nevertheless provided a solid operating baseline. Revenues increased 19% year over year to $2.89 billion, while adjusted earnings per share (EPS) rose 28% to $2.80. Total procedures increased 1", "url": "https://finance.yahoo.com/healthcare/articles/isrg-trades-premium-p-e-144200115.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T14:42:00+00:00", "published_display": "10 Aug 2026 14:42", "sentiment": "positive", "sentiment_pct": 87, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.19, "duplicate_count": 1, "topics": ["Earnings", "Earnings Per Share", "Fda Approval", "Guidance", "Medical Instruments", "Revenue Growth"]}, {"title": "Can Johnson & Johnson (JNJ) Challenge Intuitive Surgical (ISRG) After Ottava\u2019s FDA Approval?", "summary": "Johnson & Johnson (NYSE:JNJ) has officially entered the U.S. soft-tissue robotic surgery market after receiving FDA De Novo authorization for its OTTAVA robotic surgical system. The authorization represents an important milestone for J&J's MedTech ambitions, but the company is entering a market in which Intuitive Surgical (NASDAQ:ISRG) already has an extensive installed base, established surgeon relationships, and a rapidly expanding da Vinci 5 platform. The question for investors is not whether OTTAVA can become a viable product, but whether Johnson & Johnson (NYSE:JNJ) can convert its differ", "url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-challenge-intuitive-124242559.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T12:42:42+00:00", "published_display": "10 Aug 2026 12:42", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.208, "duplicate_count": 1, "topics": ["Fda Approval", "Financial Results", "Healthcare", "Medtech", "Robotic Surgery"]}, {"title": "ACCESS Announces Multi-Year Strategic Agreement to Bring Advanced Cardiac Electrophysiology Technologies to Ambulatory Surgery Centers", "summary": "Agreement supports ACCESS-affiliated ASCs in adopting the CARTO\u2122 System and its integrated portfolio of mapping, intracardiac imaging, radiofrequency ablation and pulsed field ablation technologies NEW YORK, August 10, 2026--(BUSINESS WIRE)--ACCESS, through its physician-led group purchasing organization, ACCESS GPO, today announced a multi-year preferred portfolio agreement with Johnson & Johnson to support the adoption of advanced cardiac electrophysiology technologies in ambulatory surgery centers (ASC) across the United States. The agreement encompasses an integrated portfolio of three-dim", "url": "https://finance.yahoo.com/healthcare/articles/access-announces-multi-strategic-agreement-110000847.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T11:00:00+00:00", "published_display": "10 Aug 2026 11:00", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.128, "duplicate_count": 1, "topics": ["Ambulatory Surgery Centers", "Cardiovascular Care", "Electrophysiology"]}, {"title": "Johnson & Johnson (JNJ) Reaches $5.5 Billion Talc Settlement To Close Years Of Lawsuits", "summary": "Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Johnson & Johnson (NYSE: JNJ) agreed to a US$5.5b settlement to resolve tens of thousands of talc baby powder lawsuits. The deal ends decades of litigation over alleged health risks tied to the company's talc-based products. The settlement follows years of high profile trials and failed bankruptcy attempts related to the talc claims. This resolution removes a long running legal overhang and brings more clarity for Johnson & Johnson investors. Consider broadening your research to o", "url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-reaches-5-191035095.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-07T19:10:35+00:00", "published_display": "07 Aug 2026 19:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.157, "duplicate_count": 1, "topics": ["Balance Sheet", "Consumer Health", "Legal Issues", "Settlement"]}], "industry": [], "sector": []}, "total_fetched": 15, "total_unique": 15, "total_relevant": 15, "pipeline_health": {"providers_attempted": 1, "providers_with_results": 1, "raw_articles": 15, "unique_stories": 15, "duplicates_removed": 0, "relevant_stories": 15, "current_evidence": 15, "direct_evidence": 15, "eodhd_articles": 15, "eodhd": {"configured": true, "status": "healthy", "calls_used": 150, "call_budget": 500, "budget_used_pct": 30.0, "requests_made": 30, "last_success_at": "2026-08-13T03:32:12.750297+00:00", "newest_seen_at": "2026-08-13T03:18:21+00:00", "rate_limit": 1200, "rate_remaining": 1199, "last_error": "", "mapped_mentions": 3663, "unmapped_mentions": 1812}, "status": "healthy"}, "sentiment_summary": {"positive": 14, "negative": 0, "neutral": 1, "score": 69, "raw_score": 74, "total": 15, "evidence_count": 15, "effective_articles": 14.04, "direct_story_count": 15, "industry_story_count": 0, "sector_story_count": 0, "story_count": 15, "source_count": 1, "source_concentration": 1.0, "direct_share": 100, "dispersion": 11, "confidence": 82, "evidence_status": "measured", "score_version": "evidence-v4", "newest_article_at": "2026-08-12T21:13:16+00:00", "label": "Constructive news tone", "tone": "positive"}, "classifier": {"primary_event": "earnings", "primary_label": "Earnings", "confidence": 83, "events": [{"event": "earnings", "label": "Earnings", "weight": 6.0, "count": 10}, {"event": "analyst", "label": "Analyst action", "weight": 1.2, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.2, "count": 2}, {"event": "general", "label": "Market update", "weight": 0.6, "count": 1}], "positive_events": 14, "negative_events": 0, "pipeline": {"providers_attempted": 1, "providers_with_results": 1, "raw_articles": 15, "unique_stories": 15, "duplicates_removed": 0, "relevant_stories": 15, "current_evidence": 15, "direct_evidence": 15, "eodhd_articles": 15, "eodhd": {"configured": true, "status": "healthy", "calls_used": 150, "call_budget": 500, "budget_used_pct": 30.0, "requests_made": 30, "last_success_at": "2026-08-13T03:32:12.750297+00:00", "newest_seen_at": "2026-08-13T03:18:21+00:00", "rate_limit": 1200, "rate_remaining": 1199, "last_error": "", "mapped_mentions": 3663, "unmapped_mentions": 1812}, "status": "healthy"}}, "market_context": {"has_market_context": true, "latest_close": 221.9, "latest_week": "2026-08-07", "one_week_move": -1.0, "four_week_move": -1.9, "twelve_week_move": 13.7, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.969523, "market_dynamics_buy_signal": false, "relative_strength": 9.887236, "fair_value_gap": 45.7, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 47.5758, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-1.0% over one week, -1.9% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Positive news being faded", "tone": "negative", "classification": "positive_rejected", "summary": "Constructive headlines are not being rewarded by price, which raises a rejection flag.", "confidence": 82, "badges": ["Sentiment confirms active trend", "Positive but stretched"], "opportunities": ["Constructive tone aligns with the Sharemaestro trend signal."], "risks": ["Constructive tone is arriving with price materially above fair value."], "event_label": "Earnings", "sentiment_word": "constructive"}, "charts": {"sources": [{"label": "finance.yahoo.com", "count": 15}], "tiers": [{"label": "Direct company coverage", "count": 15}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 10}, {"label": "Analyst action", "count": 2}, {"label": "Regulatory and legal", "count": 2}, {"label": "Market update", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "69/100", "tone": "positive", "text": "Constructive news tone"}, {"label": "Evidence confidence", "value": "82/100", "tone": "positive", "text": "14.04 effective stories after overlap and weighting."}, {"label": "Market reaction", "value": "Positive news being faded", "tone": "negative", "text": "Constructive headlines are not being rewarded by price, which raises a rejection flag."}, {"label": "Primary event", "value": "Earnings", "tone": "positive", "text": "83/100 classification confidence."}, {"label": "Company focus", "value": "15", "tone": "positive", "text": "100% of weighted evidence is company-specific."}, {"label": "Evidence agreement", "value": "11/100", "tone": "positive", "text": "lower dispersion means the independent stories agree more closely."}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-1.0% over one week, -1.9% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Intuitive Surgical (ISRG) Beats On Q2 As Investors Ask If The Bull Case Is Priced In"}], "updated_at": "2026-08-13T03:35:25.978723+00:00", "detail_intelligence": {"headline": "Positive news being faded", "summary": "Constructive news tone is drawn from 15 fresh independent stories, including 15 company-specific items across 1 publishers.", "status": "measured", "metrics": [{"label": "Weighted tone", "value": 69, "display": "69", "tone": "positive", "note": "Constructive news tone"}, {"label": "Evidence confidence", "value": 82, "display": "82", "tone": "positive", "note": "high confidence"}, {"label": "Company focus", "value": 100, "display": "100%", "tone": "positive", "note": "15 direct stories"}, {"label": "Evidence agreement", "value": 89, "display": "89", "tone": "positive", "note": "11/100 dispersion"}], "confidence_drivers": [{"label": "Sample depth", "value": 100, "note": "14.04 effective stories"}, {"label": "Source breadth", "value": 20, "note": "1 independent publishers"}, {"label": "Direct relevance", "value": 100, "note": "company-specific evidence share"}, {"label": "Freshness", "value": 77, "note": "recency-weighted evidence"}, {"label": "Agreement", "value": 89, "note": "cross-story consistency"}, {"label": "Source independence", "value": 0, "note": "lower publisher concentration"}], "freshness": 77, "source_independence": 0, "timeline": [{"date": "2026-07-24", "label": "24 Jul", "count": 0, "score": null, "tone": "neutral", "x": 42.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-25", "label": "25 Jul", "count": 0, "score": null, "tone": "neutral", "x": 87.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-26", "label": "26 Jul", "count": 0, "score": null, "tone": "neutral", "x": 133.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-27", "label": "27 Jul", "count": 0, "score": null, "tone": "neutral", "x": 179.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-28", "label": "28 Jul", "count": 0, "score": null, "tone": "neutral", "x": 225.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-29", "label": "29 Jul", "count": 0, "score": null, "tone": "neutral", "x": 271.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-30", "label": "30 Jul", "count": 0, "score": null, "tone": "neutral", "x": 316.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-31", "label": "31 Jul", "count": 0, "score": null, "tone": "neutral", "x": 362.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-01", "label": "01 Aug", "count": 0, "score": null, "tone": "neutral", "x": 408.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-02", "label": "02 Aug", "count": 0, "score": null, "tone": "neutral", "x": 454.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-03", "label": "03 Aug", "count": 0, "score": null, "tone": "neutral", "x": 500.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-04", "label": "04 Aug", "count": 0, "score": null, "tone": "neutral", "x": 545.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-05", "label": "05 Aug", "count": 0, "score": null, "tone": "neutral", "x": 591.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-06", "label": "06 Aug", "count": 0, "score": null, "tone": "neutral", "x": 637.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-07", "label": "07 Aug", "count": 1, "score": 65, "tone": "positive", "x": 683.2, "y": 107.7, "volume_height": 8.7, "volume_y": 257.3}, {"date": "2026-08-08", "label": "08 Aug", "count": 0, "score": null, "tone": "neutral", "x": 729.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-09", "label": "09 Aug", "count": 0, "score": null, "tone": "neutral", "x": 774.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-10", "label": "10 Aug", "count": 6, "score": 74, "tone": "positive", "x": 820.6, "y": 91.3, "volume_height": 52.0, "volume_y": 214.0}, {"date": "2026-08-11", "label": "11 Aug", "count": 3, "score": 82, "tone": "positive", "x": 866.4, "y": 76.8, "volume_height": 26.0, "volume_y": 240.0}, {"date": "2026-08-12", "label": "12 Aug", "count": 5, "score": 70, "tone": "positive", "x": 912.2, "y": 98.6, "volume_height": 43.3, "volume_y": 222.7}, {"date": "2026-08-13", "label": "13 Aug", "count": 0, "score": null, "tone": "neutral", "x": 958.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}], "timeline_points": "683.2,107.7 820.6,91.3 866.4,76.8 912.2,98.6", "timeline_has_signal": true, "timeline_start": "24 Jul", "timeline_mid": "03 Aug", "timeline_end": "13 Aug", "momentum": {"label": "Improving", "tone": "positive", "recent_score": 74, "prior_score": 65, "delta": 9, "recent_count": 14, "prior_count": 1, "volume_delta": 13}, "freshness_buckets": [{"label": "Last 24 hours", "count": 5, "share": 33}, {"label": "1 to 3 days", "count": 9, "share": 60}, {"label": "4 to 7 days", "count": 1, "share": 7}, {"label": "8 to 30 days", "count": 0, "share": 0}], "source_profile": [{"label": "finance.yahoo.com", "count": 15, "share": 100, "score": 74, "tone": "positive"}], "event_profile": [{"label": "Earnings", "count": 10, "share": 67, "score": 78, "tone": "positive"}, {"label": "Analyst action", "count": 2, "share": 13, "score": 67, "tone": "positive"}, {"label": "Regulatory and legal", "count": 2, "share": 13, "score": 64, "tone": "positive"}, {"label": "Market update", "count": 1, "share": 7, "score": 65, "tone": "positive"}], "topics": [{"label": "Fda Approval", "count": 6, "share": 40}, {"label": "Earnings", "count": 6, "share": 40}, {"label": "Healthcare", "count": 5, "share": 33}, {"label": "Revenue Growth", "count": 4, "share": 27}, {"label": "Price Target", "count": 4, "share": 27}, {"label": "Medtech", "count": 4, "share": 27}, {"label": "Robotic Surgery", "count": 3, "share": 20}, {"label": "Guidance", "count": 3, "share": 20}, {"label": "Earnings Per Share", "count": 3, "share": 20}, {"label": "Biotech", "count": 3, "share": 20}], "supporting": [{"label": "Direct evidence", "text": "15 current stories are mapped specifically to JNJ."}, {"label": "Narrative agreement", "text": "Cross-story agreement is 89/100, indicating a comparatively coherent tape."}], "tempering": [{"label": "Source breadth", "text": "Only 1 publisher currently contribute to the measured read."}, {"label": "Price disagreement", "text": "Constructive headlines are not being rewarded by price, which raises a rejection flag."}], "supporting_heading": "What supports the read", "tempering_heading": "What tempers the read", "latest_observation": {"title": "Intuitive Surgical (ISRG) Beats On Q2 As Investors Ask If The Bull Case Is Priced In", "summary": "Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Intuitive Surgical (ISRG) shook investors after reporting strong Q2 2026 revenue and earnings that beat expectations, while revealing slower U.S. procedure growth and rising competitive pressure from Johnson & Johnson and Chinese robotic surgery platforms. See our latest analysis for Intuitive Surgical. The Q2 surprise arrives after a tough stretch for Intuitive Surgical, with the share price down 28.6% year to date and the 1 year total shareholder return ", "url": "https://finance.yahoo.com/markets/stocks/articles/intuitive-surgical-isrg-beats-q2-211316667.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T21:13:16+00:00", "published_display": "12 Aug 2026 21:13", "sentiment": "positive", "sentiment_pct": 85, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.295, "duplicate_count": 1, "topics": ["Earnings", "Medical Equipment", "Revenue Growth", "Share Price", "Shareholder", "Split"]}, "article_count": 15, "updated_at": "2026-08-13T02:17:13.517083+00:00"}, "price_sentiment_path": {"available": true, "price_points": [{"x": 42.0, "y": 148.5, "label": "13 Feb 2026", "close": 203.35, "index": 100.0}, {"x": 77.6, "y": 149.9, "label": "20 Feb 2026", "close": 202.96, "index": 99.8}, {"x": 113.3, "y": 135.6, "label": "27 Feb 2026", "close": 207.16, "index": 101.9}, {"x": 148.9, "y": 151.0, "label": "06 Mar 2026", "close": 202.64, "index": 99.6}, {"x": 184.5, "y": 121.3, "label": "13 Mar 2026", "close": 211.38, "index": 103.9}, {"x": 220.1, "y": 150.5, "label": "20 Mar 2026", "close": 202.79, "index": 99.7}, {"x": 255.8, "y": 131.1, "label": "27 Mar 2026", "close": 208.5, "index": 102.5}, {"x": 291.4, "y": 122.2, "label": "03 Apr 2026", "close": 211.13, "index": 103.8}, {"x": 327.0, "y": 150.6, "label": "10 Apr 2026", "close": 202.74, "index": 99.7}, {"x": 362.6, "y": 168.4, "label": "17 Apr 2026", "close": 197.51, "index": 97.1}, {"x": 398.3, "y": 182.7, "label": "24 Apr 2026", "close": 193.28, "index": 95.0}, {"x": 433.9, "y": 178.7, "label": "01 May 2026", "close": 194.47, "index": 95.6}, {"x": 469.5, "y": 204.2, "label": "08 May 2026", "close": 186.95, "index": 91.9}, {"x": 505.2, "y": 176.2, "label": "15 May 2026", "close": 195.19, "index": 96.0}, {"x": 540.8, "y": 157.2, "label": "22 May 2026", "close": 200.8, "index": 98.7}, {"x": 576.4, "y": 178.0, "label": "29 May 2026", "close": 194.68, "index": 95.7}, {"x": 612.0, "y": 151.6, "label": "05 Jun 2026", "close": 202.45, "index": 99.6}, {"x": 647.7, "y": 135.7, "label": "12 Jun 2026", "close": 207.15, "index": 101.9}, {"x": 683.3, "y": 164.1, "label": "19 Jun 2026", "close": 198.76, "index": 97.7}, {"x": 718.9, "y": 84.0, "label": "26 Jun 2026", "close": 222.4, "index": 109.4}, {"x": 754.6, "y": 58.7, "label": "03 Jul 2026", "close": 229.85, "index": 113.0}, {"x": 790.2, "y": 71.2, "label": "10 Jul 2026", "close": 226.15, "index": 111.2}, {"x": 825.8, "y": 82.9, "label": "17 Jul 2026", "close": 222.7, "index": 109.5}, {"x": 861.4, "y": 55.8, "label": "24 Jul 2026", "close": 230.7, "index": 113.4}, {"x": 897.1, "y": 78.2, "label": "31 Jul 2026", "close": 224.1, "index": 110.2}, {"x": 932.7, "y": 85.7, "label": "07 Aug 2026", "close": 221.9, "index": 109.1}], "sentiment_points": [{"x": 692.1, "y": 122.6, "label": "20 Jun 2026", "score": 54}, {"x": 702.0, "y": 120.8, "label": "22 Jun 2026", "score": 55}, {"x": 702.4, "y": 120.8, "label": "22 Jun 2026", "score": 55}, {"x": 706.0, "y": 122.6, "label": "23 Jun 2026", "score": 54}, {"x": 716.1, "y": 119.0, "label": "25 Jun 2026", "score": 56}, {"x": 728.8, "y": 124.5, "label": "27 Jun 2026", "score": 53}, {"x": 739.0, "y": 119.0, "label": "29 Jun 2026", "score": 56}, {"x": 744.3, "y": 122.6, "label": "30 Jun 2026", "score": 54}, {"x": 749.1, "y": 120.8, "label": "01 Jul 2026", "score": 55}, {"x": 749.1, "y": 120.8, "label": "01 Jul 2026", "score": 55}, {"x": 755.6, "y": 117.1, "label": "03 Jul 2026", "score": 57}, {"x": 773.4, "y": 124.5, "label": "06 Jul 2026", "score": 53}, {"x": 784.8, "y": 128.2, "label": "08 Jul 2026", "score": 51}, {"x": 789.8, "y": 130.0, "label": "09 Jul 2026", "score": 50}, {"x": 795.1, "y": 128.2, "label": "10 Jul 2026", "score": 51}, {"x": 796.6, "y": 128.2, "label": "11 Jul 2026", "score": 51}, {"x": 810.1, "y": 126.3, "label": "13 Jul 2026", "score": 52}, {"x": 815.7, "y": 130.0, "label": "15 Jul 2026", "score": 50}, {"x": 826.2, "y": 124.5, "label": "17 Jul 2026", "score": 53}, {"x": 830.5, "y": 128.2, "label": "17 Jul 2026", "score": 51}, {"x": 832.8, "y": 126.3, "label": "18 Jul 2026", "score": 52}, {"x": 835.7, "y": 128.2, "label": "18 Jul 2026", "score": 51}, {"x": 846.4, "y": 128.2, "label": "21 Jul 2026", "score": 51}, {"x": 846.6, "y": 126.3, "label": "21 Jul 2026", "score": 52}, {"x": 850.8, "y": 126.3, "label": "21 Jul 2026", "score": 52}, {"x": 851.8, "y": 122.6, "label": "22 Jul 2026", "score": 54}, {"x": 852.3, "y": 120.8, "label": "22 Jul 2026", "score": 55}, {"x": 860.3, "y": 124.5, "label": "23 Jul 2026", "score": 53}, {"x": 860.9, "y": 124.5, "label": "23 Jul 2026", "score": 53}, {"x": 864.5, "y": 124.5, "label": "24 Jul 2026", "score": 53}, {"x": 867.4, "y": 120.8, "label": "25 Jul 2026", "score": 55}, {"x": 880.2, "y": 124.5, "label": "27 Jul 2026", "score": 53}, {"x": 882.6, "y": 122.6, "label": "28 Jul 2026", "score": 54}, {"x": 891.8, "y": 126.3, "label": "29 Jul 2026", "score": 52}, {"x": 896.9, "y": 128.2, "label": "30 Jul 2026", "score": 51}, {"x": 904.4, "y": 126.3, "label": "01 Aug 2026", "score": 52}, {"x": 905.8, "y": 126.3, "label": "01 Aug 2026", "score": 52}, {"x": 909.9, "y": 128.2, "label": "02 Aug 2026", "score": 51}, {"x": 912.1, "y": 128.2, "label": "02 Aug 2026", "score": 51}, {"x": 915.8, "y": 126.3, "label": "03 Aug 2026", "score": 52}, {"x": 927.1, "y": 126.3, "label": "05 Aug 2026", "score": 52}, {"x": 958.0, "y": 102.4, "label": "11 Aug 2026", "score": 65}], "price_path": "42.0,148.5 77.6,149.9 113.3,135.6 148.9,151.0 184.5,121.3 220.1,150.5 255.8,131.1 291.4,122.2 327.0,150.6 362.6,168.4 398.3,182.7 433.9,178.7 469.5,204.2 505.2,176.2 540.8,157.2 576.4,178.0 612.0,151.6 647.7,135.7 683.3,164.1 718.9,84.0 754.6,58.7 790.2,71.2 825.8,82.9 861.4,55.8 897.1,78.2 932.7,85.7", "sentiment_path": "692.1,122.6 702.0,120.8 702.4,120.8 706.0,122.6 716.1,119.0 728.8,124.5 739.0,119.0 744.3,122.6 749.1,120.8 749.1,120.8 755.6,117.1 773.4,124.5 784.8,128.2 789.8,130.0 795.1,128.2 796.6,128.2 810.1,126.3 815.7,130.0 826.2,124.5 830.5,128.2 832.8,126.3 835.7,128.2 846.4,128.2 846.6,126.3 850.8,126.3 851.8,122.6 852.3,120.8 860.3,124.5 860.9,124.5 864.5,124.5 867.4,120.8 880.2,124.5 882.6,122.6 891.8,126.3 896.9,128.2 904.4,126.3 905.8,126.3 909.9,128.2 912.1,128.2 915.8,126.3 927.1,126.3 958.0,102.4", "price_change": 9.1, "sentiment_change": 11, "latest_close": 221.9, "start_label": "13 Feb", "mid_label": "15 May", "end_label": "07 Aug"}, "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}